Metabolic dysfunctions in non-antiretroviral treated HIV/AIDS patients by Isezuo, S.A & Makusidi, M.A
patient units of the medical department of Usmanu
Danfodiyo University Teaching Hospital, Sokoto,
Nigeria. Inclusion criteria were as follows:
1.Two positive enzyme linked immunosorbent assay
(ELISA) test for HIV-1 and HIV-2 done using two
different kits.
2.Satisfying the case definition ofAIDS .
3.Informed consent for HIV screening and
participation in the study.
Patients with lipid altering conditions including
systemic hypertension, diabetes mellitus,
hypothyroidism, renal and hepatobiliary diseases
were excluded using clinical and basic biochemical
parameters. Other exclusion criteria included use of
lipid lowering and antiretroviral drugs, cigarette
smoking and alcohol ingestion.
Demographic data including age, marital status and
occupation were obtained. Anthropometric indices
including height and weight, and waist, hip and mid
upper arm circumferences were measured with
subjects lightly clothed and without shoes. Body
mass index was calculated. Blood pressure was
measured using standard procedures . Forty age, sex
and exclusion criteria-matched HIV seronegative
individuals were randomly selected from blood






Metabolic and morphologic disorders have been
d es c r ib e d i n h u man im mu no d ef i c i e n cy
virus/acquired immune deficiency syndrome
(HIV/AIDS) patients treated with protease inhibitor
based highly active antiretroviral therapy (HAART)
. Morphologic abnormalities including central
obesity and dorsocervical fat accumulation occur in
30-50% of such patients, while metabolic
derangements include impaired glucose tolerance
(46%), diabetes mellitus (1-7%) and dyslipidaemia
(15-30%) . HIV/AIDS is however a multisystemic
disease with potential for alteration of endocrine and
metabolic functions via virus-induced cytopathy, and
opportunistic infections and diseases. In Nigeria,
about 5% of the population is afflicted with
HIV/AIDS . This study aimed at determining the
metabolic derangements in anti-retroviral treatment
naïve HIV/AIDS patients.
Forty-eight indigenous Nigerians (males, 82%;
females, 18% aged 34.8 ± 9.1 years (range: 22-52
years) with HIV/AIDS were consecutively recruited
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AIDS related metabolic and morphologic disorders have been attributed to protease inhibitor based
antiretroviral therapy. HIV/AIDS is however a multi-systemic disease with potential for alteration of metabolic and
endocrine functions.
To determine if metabolic disorders occur in non-antiretroviral treated HIV/AIDS patients.
Case control study of prospectively recruited 48 HIV seropositive patients, and randomly selected age
and sex-matched controls. Main outcome measures included plasma lipid concentrations and intravenous glucose
tolerance measured using glucose assimilation coefficient, K. A K-value less than 1.2 constituted an impaired
glucose tolerance.
Compared to the controls, HIV/AIDS patients had significantly lower glucose assimilation coefficient (1.5
± 0.5 versus 2.7 ± 0.9; p < 0.001); higher proportion of individuals with impaired glucose tolerance (35.4% versus
7.5%; P = 0.01); and higher plasma triglyceride concentration (166.5 ± 20.7 mg/dL versus 148.9 ± 13.5 mg/dL; p =
0.04). The proportion of patients with hypertriglyceridaemia was also significantly higher among patients than
controls (56.3% versus 17.5%; p = 0.04).
Metabolic dysfunctions occur in HIV/AIDS independent of antiretroviral therapy. Routine monitor of
plasma lipids and glucose is therefore advocated in HIV/AIDS patients.
HIV/AIDS, metabolic dysfunctions.
Intravenous glucose tolerance test (IGTT)
StatisticalAnalysis
RESULTS
After about 10 hours of overnight fasting, subjects
were rested for 15 minutes in supine position.
Intravenous glucose tolerance test was carried out .
A cannula, size I6G was inserted into a vein in the
aiitecubital fossa and left in-situ at about 7.30 am on
each day of the IGTT. About 10mls of fasting blood
was withdrawn into fluoride oxalate bottle for
fasting blood sugar, plasma lipid concentrations,
electrolytes, urea, creatinine and uric acid.
Subsequently, 0.5 gm/kg body weight of 50%
glucose was given intravenously over 2-4 minutes.
About 3mls of blood was withdrawn immediately
(within 2 minutes of glucose injection) and at 10, 20,
30, 40, 50 and 60 minutes after the end of glucose
injection. The blood samples were put into separate
fluoride oxalate bottles, appropriately labelled with
exact time of blood sampling indicated and sent
immediately to the laboratory for blood glucose
determination using glucose oxidase test .
Intravenous glucose tolerance test was reported as
glucose assimilation coefficient (K) calculated from
a standard formula: K = 0.693 x 100 x t ; where t is
the time taken in minutes for the blood glucose
concentration immediately after glucose injection to
be reduced to half of its value. K values were
interpreted as follows (impaired glucose tolerance:
K < 1.2) (borderline: K = 1.2-1.29) (normal: K = 1.3)
. Glucose tolerance curve was obtained by plotting
the mean blood glucose concentration (y-axis)
against time in minutes (x-axis).
Total plasma cholesterol, high-density lipoprotein
(HDL) cholesterol, low density lipoprotein (LDL)
cholesterol and triglyceride were determined. Total
plasma cholesterol > 200 mg/dl, triglyceride > 150
mg/dl, LDL-C > 135 mg/dl and HDL-C < 40 mg/dl
constituted dyslipidaemia.
Data entry and analysis were done using Statistical
Package for Social Sciences (SPSS) software.
Means were presented as mean ± standard deviation.
Independent t-test (2- tailed) was utilised in
comparing continuous biochemical variables
between patients and controls. The categorical
variables among the two groups were compared
using chi-square test with Yates's correction. A P-
value < 0.05 was considered statistically significant.
The baseline characteristics of patients are shown in
Tables 1. Majority of them were young married male
civil servants with weight loss, and chronic fever,
cough and diarrhoea. The biochemica l
characteristics of patients and controls are compared
in Table 2. Compared to the controls, patients had
significantly lower mean glucose assimilation





0.001), and higher proportion of individuals with
impaired glucose tolerance (35.4% versus 7.5%; X =
8.16; p = 0.01). The glucose tolerance curve of




Demographic and clinical characteristics
of HIV/AIDS patients.
Glucose Tolerance Curve of Patients and
Controls.
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Table 2:Comparison of the biochemical parameters of HIV/AID patients and controls.
377
DISCUSSION
The general characteristics of IHV/AIDS patients
are similar to the previous data from our centre . The
current report shows that metabolic derangements
occur in non-antiretroviral treated HIV/AIDS
patients, though their frequencies are lower than that
reported among those on HAART In a
comparative analysis of insulin sensitivity in HIV
seropositive patients receiving protease inhibitors,
HIV scropositive patients who were not on protease
inhibitors and HIV scronegative controls, previous
workers noted that insulin sensitivity was lower in
protease inhibitor treated HIV scropositive patients
compared to controls. Further, compared to the
controls, insulin sensitivity was also lower in HIV
scropositive patients who were not on protease
inhibitors.
This suggests that factors other than antiretroviral
drugs may be contributory to the pathogenesis of
AIDS related insulin insensitivity, and metabolic
and morphologic disorders . Tendencies to
proatherogenicity and lipid disorders have been
previously reported in other chronic infections such
as Chlamydia pneumonia . The mechanisms
underlying metabolic disorders in HIV/AIDS have
not been clearly defined.An inverse relationship was
previously thought to exist between HIV/AIDS and
diabetes mellitus . This hypothesis was based on the
progressive depletion of CD4 helper lymphocytes in








beta cell destruction in diabetes mellitus . However,
CD4 lymphocyte depletion in HIV infection is
variable and may still be sufficient to mediate beta
cell destruction. HIV itself has a virally encoded
molecule (Vpr) that may activate glucocorticoid
receptor . .HIV/AIDS induced immune
reconstitution has also been associated with
inflammatory responses including increased tumour
necrosis factor alpha, interferon alpha, interleukins
and cortisol . These changes may lead to decreased
lipoprotein lipase activity, increase triglyceride
synthesis and decrease triglyceride catabolism . The
major significance of metabolic alterations in
HIV/AIDS is the potential for accelerated
atheroselerosis
Further, other cardiovascular abnormalities such as
myocarditis, pericarditis, pericardial effusion and
dilated cardiomyopathy have been described in
HIV/AIDS patients . HIV/AIDS is therefore a
potential risk factor for increased cardiovascular
morbidity and mortality.
In conclusion, metabolic cardiovascular risk factors
occur in HIV/AIDS patients independent of
antiretroviral therapy. Blood sugar and lipid
concentrations should therefore be monitored in these
patients irrespective of antiretroviral treatment.
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